Revenue decreased 1.2%
Revenue changed -1.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$863.7M→$853.1M3 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed -1.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
SBC / revenue changed -54 basis points from the comparable as-filed period.
Stock-based compensation changed -8.1% from the comparable as-filed period.
Research & development changed +0.3% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.